Inpatient and Outpatient Orderable

Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

Synonyms

ENCEPHALOPATHY AUTOIMMUNE EVAL, S
ENS2
LAB10600

Cerner Name

Clinical Info

Mayo code ENS2
Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in serum specimens

The following accompaniments should increase of suspicion for autoimmune encephalopathy:
-Headache
-Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Inflammatory cerebral spinal fluid (or isolated protein elevation)
-Neuroimaging signs suggesting inflammation

Evaluating limbic encephalitis (noninfectious)

Directing a focused search for cancer

Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Container

Red Top Tube

Collection Instructions

Container/Tube: Gold Top or Red Top Tube
Specimen: 4.0 mL serum (2.5 mL min)

Patient Preparation:
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.

Specimen Volume

4.0 mL serum (2.5 mL min)

Transport Instructions

Refrigerated

Specimen Stability

72 Hours Room Temperature
28 Days Refrigerated or Frozen

Methodology

Indirect Immunofluorescence Assay (IFA)
Cell-Binding Assay (CBA)
Western Blot (WB)
Immunoblot (IB)
Radioimmunoassay (RIA)

Days Performed

TAT: 9-13 Days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT

86255 x 23
86341
LOINC Code: 94697-0

PDM

1759374

Only Orderable at Locations:

Orderable Everywhere

Results

Component Name	Base Name	Common Name	External Name
ENCEPHALOPATHY, INTERPRETATION, S	ENCEPINTRPS	ENCEP INTERP S	Encephalopathy, Interpretation, S
IFA NOTES	IFANOTES	IFA NOTES	IFA Notes
NEURONAL (V-G) K+ CHANNEL AB, S	VGKCHANAB	NEURONAL VOLTAGE GATED K CHANNEL AB	Neuronal (V-G) K+ Channel Ab, S
AMPA-R ABCBA	AMPARABCBA	AMPA R ABCBA	AMPA-R Ab CBA, S
AMPHIPHYSIN AB, S	AMPHIPABS	AMPHIP AB S	Amphiphysin Ab, S
AGNA-1, S	AGNA1S	AGNA 1 S	AGNA-1, S
ANNA-1, S	ANNA1S	ANNA 1 S	ANNA-1, S
ANNA-2, S	ANNA2S	ANNA 2 S	ANNA-2, S
ANNA-3, S	ANNA3S	ANNA 3 S	ANNA-3, S
CASPR2-IGG CBA, S	CASPR2IGCBAS	CASPR2 IGG CBA S	CASPR2-IgG CBA, S
REFLEX ADDED	REFADD	REFLEX ADDED	Reflex Added
CRMP-5-IGG WESTERN BLOT	CR5IGWESBLOT	CR 5 IGG WES BLOT	CRMP-5-IgG, S
DPPX AB CBA, S	DPPXABCBAS	DPPX AB CBA, S	DPPX Ab CBA, S
GABA-B- RECEPTOR ANTIBODY BY CBA, SERUM	GABABABCBA	GABA B ABCBA	GABA-B Ab CBA, S
GLUTAMIC ACID DECARBOXYLASE ANTIBODY	GADAB	GLUTAMIC ACID DECARB AB	GAD65 Ab Assay, S
GLIAL FIBRILLARY ACIDIC PROTEIN.ALPHA SUBUNIT AB IGG	GFAPIFA	GLIAL FIBRILLARY ACIDIC PROTEIN ALPHA SUBUNIT AB IGG	GFAP IFA, S
METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG	MGLUR1ABIFA	METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG	mGluR1 Ab IFA, S
LGI1-IGG CBA, S	LGI1IGGCBAS	LGGI1 IGG CBA S	LGI1-IgG CBA, S
NEUROCHONDRIN AB	NEUROCHIFA	NEUROCHONDRIN AB	Neurochondrin IFA, S
DIPEPTIDYL AMINOPEPTIDASE-LIKE PROTEIN 6 AB IGG	DPPXABIFA	DIPEPTIDYL AMINOPEPTIDASE LIKE PROTEIN 6 AB IGG	Dipeptidyl aminopeptidase-like protein 6 AB IGG
NMDA-R ABCBA	NMDARABCBA	NMDA R ABCBA	NMDA-R Ab CBA, S
PCA-1, S	PCA1S	PCA 1 S	PCA-1, S
PCA-2, S	PCA2S	PCA 2 S	PCA-2, S
PCA-TR, S	PCATRS	PCA TR S	PCA-Tr, S
NEUROCHONDRIN IFA, CSF	NEURCHAB	NEUROCHONDRIN IFA, CSF	Neurochondrin IFA, CSF
PURKINJE CELL CYTOPLASMIC AB TYPE 2	PURCYTO2	PURKINJE CELL CYTOPLASMIC AB TYPE 2	PCA-2, CSF
PURKINJE CELL CYTOPLASMIC AB TYPE 1	PURCYTO1	PURKINJE CELL CYTOPLASMIC AB TYPE 1	PCA-1, CSF
NMDA-R AB CBA, CSF	NMDARABCBA	NMDA R AB CBA, CSF	NMDA-R Ab CBA, CSF
NIF IFA, CSF	NIFIFA	NIF IFA, CSF	NIF IFA, CSF
NMDAR- ABCBAC	NMDARABCBAC	NMDAR ABCBAC	NMDA-R Ab CBA, S

Result Interpretation

See Report

Forms

LAB10600

Search: .supercomplete-item { width: 600px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; } $(document).ready(function() { $("#search_input").supercomplete(); });